Accessibility settings

Published on in Vol 10 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/54178, first published .
Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Journals

  1. Liu W, Niu J, Huo Y, Zhang L, Han L, Zhang N, Yang M. Role of circular RNAs in cancer therapy resistance. Molecular Cancer 2025;24(1) View
  2. Asper N, Witschel H, von Stockar L, Laurenzi E, Kolberg H, Vetter M, Roth S, Kullak-Ublick G, Trojan A. Using Machine Learning Approaches on Dynamic Patient-Reported Outcomes to Cluster Cancer Treatment-Related Symptoms. Current Oncology 2025;32(6):334 View
  3. Aicher A, Vetter M, Blum D, Trojan A. Revisiting the OGIPRO Trial: Dynamic Electronic Patient-Reported Outcomes Compared with EQ-5D-5L in HER2-Positive Breast Cancer. Cancers 2026;18(4):614 View